SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as investors debate whether the low-market-cap meme coin is a legitimate scaling opportunity or a high-risk pump-and-dump scheme. The community is actively tracking whale wallet movements and liquidity patterns, with participants weighing the potential for massive gains against warnings of a total rug pull.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as retail traders scramble for exposure to AI leaders like OpenAI, Anthropic, and SpaceX, fueling a meme-like frenzy that has sent the stock soaring despite warnings of extreme overvaluation relative to its net asset value. Community members are actively debating the sustainability of this parabolic run, with many highlighting that the limited tradable float due to lockup periods is creating intense volatility and aggressive short-squeeze dynamics.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is capturing significant retail interest driven by its concentrated exposure to private tech leaders like SpaceX and Anthropic, which investors are tracking closely ahead of potential IPO activity. The community is actively debating the stock's substantial premium to its net asset value, with traders comparing its valuation mechanics to other proxy investment funds in the sector.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is capturing significant investor attention following promising Phase 1 clinical data for its leukemia candidate, TERN-701, which has sparked intense debate over the company's valuation and potential as an acquisition target. The community is deeply divided between bulls citing the drug's best-in-disease profile and analysts raising price targets, while bears express skepticism about the sustainability of the current valuation and the potential for near-term dilutive share offerings.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing intense focus as investors weigh the potential synergy of a rumored SpaceX-Tesla partnership and the ambitious 'Terafab' in-house silicon project against concerns over slowing EV sales, valuation, and aggressive capital expenditure. The community remains deeply polarized, with bulls positioning for a potential squeeze fueled by SpaceX IPO anticipation and AI infrastructure expansion, while bears continue to highlight declining earnings and significant execution risks.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is experiencing significant volatility following a leaked draft of the Clarity Act, which proposes banning stablecoin yield-sharing models and has sparked intense debate over the long-term viability of the company's revenue model. While some retail investors are buying the dip and betting on Circles role as a future payment utility, others remain skeptical, pointing to aggressive insider selling and ongoing regulatory uncertainty as signs of an overvalued asset.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investors focus on recent positive updates regarding Medicare coverage prospects and the company's strong clinical test volume growth, which is being driven by its pivotal role in the precision oncology ecosystem alongside Tempus. The community is actively debating the company's long-term potential as a 'picks and shovels' leader in cancer diagnostics, closely monitoring upcoming earnings and the timing of regulatory milestones that could trigger a significant re-rating of the stock.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending as the stock undergoes significant volatility and a sharp multi-day decline, sparking intense debate among retail traders regarding the cause of the selloff. The community is actively discussing the stock's high valuation, frequent insider selling, and potential institutional manipulation, while many long-term shareholders remain focused on the company's dominant market position and growth outlook in the public safety sector.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors debate whether the company's AI-driven platform and mortgage innovation represent a high-growth turnaround or a business model inherently vulnerable to high mortgage rates and macroeconomic pressures. The community remains intensely polarized, with bulls highlighting the firms increasing acquisition volume and leadership strategy, while bears continue to focus on the company's profitability challenges and its sensitivity to broader market volatility.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is trending as traders debate its long-term viability amid ongoing supply reduction rumors and institutional classification as a digital commodity. While the community remains divided between long-term holders expressing bullish conviction and skeptics labeling the asset a high-risk gamble, activity is surging as investors closely monitor whale accumulation patterns and potential market shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX Hope see a meaningful rebound on the upward trend tomorrow.

The sentiment was very strong yesterday, with shares rising +11%, and continued into this morning’s premarket following news that China Macau’s regulatory authority approved Anktiva for the treatment of bladder cancer. The drug has demonstrated remarkable efficacy, including an impressive complete response rate of 71% and a median duration of response of 26.6 months.

Unfortunately, the FDA’s warning after market open regarding IBRX’s inaccurate marketing claims in podcasts and promotional materials dampened the momentum. 

https://finance.yahoo.com/sectors/healthcare/articles/immunitybio-rises-china-nod-bladder-164400372.html

Nick

tamikajw

Muddy Waters

Dan Mac

BUY N HOLD IS DEAD

HeadHunter

Delbert Grady

IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.

Yahoo Finance

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

StockTwits for iOS

ImmunityBio Inc

 Hope see a meaningful rebound on the upward trend tomorrow.

The sentiment was very strong yesterday, with shares rising +11%, and continued into this morning’s premarket following news that China Macau’s regulatory authority approved Anktiva for the treatment of bladder cancer. The drug has demonstrated remarkable efficacy, including an impressive complete response rate of 71% and a median duration of response of 26.6 months.

Unfortunately, the FDA’s warning after market open regarding IBRX’s inaccurate marketing claims in podcasts and promotional materials dampened the momentum. 



Btcinvestor great

@Btcinvestoram gap up at the open, V recovery!

StockTwits Web

@Btcinvestoram Yep. At least the letter came today on a red day for the entire market and made the effect look worse than it really is.  Let’s get it back tomorrow.

 Yep. At least the letter came today on a red day for the entire market and made the effect look worse than it really is.  Let’s get it back tomorrow.